1/2 @Bloomberg went inside Amgen @deCODE genetics in Iceland to get an exclusive look at how Amgen is using human DNA to shape our distinct approach to obesity research: https://t.co/gNkhkbNRgL
$AMGN
No two obesity journeys look the same, which is why real progress in obesity care starts with listening. At #HLTHUSA, we’re putting that into practice. Watch Amy share her experience and learn why continued dialogue and understanding matter.
🔗 https://t.co/jNm4pdBfXO
At @ACRheum’s #ACR26, researchers, clinicians and community voices surfaced unanswered questions in rare autoimmune and inflammatory diseases.
Byeong Yoon explains how those exchanges can guide future research. ▶️
As we head into #HLTHUSA and #ObesityWeek, one thing is clear: the future of obesity care will be shaped by the conversations we have and actions we take together.
By bringing together diverse voices, these meetings create opportunities to address the significant burdens that continue to impact millions of people living with obesity.
#SjogrensDisease news: Amgen presented late-breaking Phase 3 results at #ACR26. The study showed improvements in systemic disease activity and symptoms.
🔗 https://t.co/0Xw2WaDQTL
$AMGN
At AHA #ScientificSessions26, Amgen presented data highlighting the cost effectiveness of intensive LDL-C lowering, building on years of established clinical evidence.
Read the press release: https://t.co/FJl0d8enKp
$AMGN
Why do some people develop heart disease while others don’t?
Amgen research leader and AHA Population Research Prize recipient Pradeep Natarajan shares insights in a new Q&A article.
https://t.co/RpK62Reive
B cells are built to protect us. But in autoimmune disease, they can become dysregulated and contribute to disease.
Amgen researchers are exploring whether targeting CD19 could help address that🔬
📢 Amgen’s real-world study shows that treatment decisions to lower LDL-C impacts heart attack risk in ASCVD patients.
The findings prompt a closer look at how we approach LDL-C lowering in clinical practice.
🔗 https://t.co/ePS9dMVLDY
$AMGN
Amgen reports Q3 2026 earnings: https://t.co/UqJuvtR4z6
Amgen delivered another strong quarter, reflecting the performance our strategy was designed to achieve.
Safe Harbor: https://t.co/ZQwgA733OW
$AMGN
1/2 @Bloomberg went inside Amgen @deCODE genetics in Iceland to get an exclusive look at how Amgen is using human DNA to shape our distinct approach to obesity research: https://t.co/gNkhkbNRgL
$AMGN
At AHA #ScientificSessions26, Amgen is adding to its extensive base of cardiovascular evidence, with new research exploring LDL-C management, long-term outcomes and the economic considerations of care.
Explore our abstracts ⬇️
Every story is personal. Every voice can help bring our mission into focus. Meet people whose experiences with cancer, cardiovascular disease, rare disease and obesity have shaped their lives and perspectives.
At Amgen, serving patients is our mission. We’re honored to be named to @TIME World’s Best Companies 2026 list: https://t.co/LJEYfkP4t0
Innovation has deep roots in Massachusetts, and Amgen is proud to have been part of its life sciences community for 25 years. From our research center in Cambridge, our teams continue to push the boundaries of science to advance medicines for patients around the world.
Learn more about our history in Massachusetts: https://t.co/ELEFzvJ0yT
Amgen today announced the appointment of David W. Gibbs, former president and CEO of Yum! Brands, to its Board of Directors. He brings experience leading global consumer brands and building direct customer relationships.
https://t.co/vhDmtqXRto